Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Exelixis
Exelixis
Analysts throw cold water on Exelixis and Roche's prostate cancer data, putting the pair a further step behind Novartis
Endpoints
Tue, 05/25/21 - 11:08 am
Exelixis
Cabometyx
Roche
Tecentriq
prostate cancer
ASCO 2021: Watch for Sanofi/Sloan Kettering, Incyte, Exelixis and AstraZeneca
BioSpace
Thu, 05/20/21 - 12:35 pm
ASCO 2021
Sanofi
Sloane Kettering
Incyte
AstraZeneca
Exelixis
oncology
ASCO: Exelixis releases more details on Cabometyx thyroid cancer data that wooed Ipsen
Fierce Pharma
Thu, 05/20/21 - 12:15 pm
ASCO 2021
Ipsen
Exelixis
Cabometyx
thyroid cancer
clinical trials
Exelixis' Cabometyx scores backing from Ipsen in thyroid cancer, with full data release set for ASCO
Fierce Pharma
Wed, 05/12/21 - 11:39 pm
Exelixis
Cabometyx
Ipsen
thyroid cancer
Bristol Myers, Exelixis snag Opdivo-Cabometyx kidney cancer nod to challenge Merck, Pfizer
Fierce Pharma
Mon, 01/25/21 - 11:09 am
Bristol-Myers Squibb
Exelixis
Opdivo
Cabometyx
kidney cancer
FDA
Exelixis Gets FDA Approval for Cabometyx in Combination Therapy for Front-Line RCC
Motley Fool
Sat, 01/23/21 - 11:35 pm
Exelixis
FDA
Cabometyx
Cometriq
advanced renal cell carcinoma
Exelixis, NBE join forces for discovery and development of ADCs for cancer
Pharmaceutical Business Review
Wed, 09/9/20 - 10:32 am
Exelixis
NBE Therapeutics
antibody-drug conjugate
oncology
Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer
Yahoo/Zacks.com
Tue, 08/25/20 - 11:19 am
Exelixis
Cabometyx
FDA
kidney cancer
renal cell carcinoma
Bristol-Myers Squibb
Opdivo
Exelixis initiates phase 3 trial of Cabozantinib/Atezolizumab combo in prostate cancer
Pharmaceutical Business Review
Wed, 07/1/20 - 11:03 am
Exelixis
cabozantinib
Cabometyx
Tecentriq
metastatic castration-resistant prostate cancer
clinical trials
Exelixis lands PhIII kidney cancer win with Bristol Myers in their hunt for $4 billion
Endpoints
Mon, 04/20/20 - 11:59 pm
Bristol-Myers Squibb
Opdivo
Exelixis
Cabometyx
renal cell carcinoma
kidney cancer
clinical trials
2 Biotechs Battling Against Kidney Cancer
Motley Fool
Sun, 04/19/20 - 11:06 pm
kidney cancer
Nektar
Exelixis
Why AnaptysBio, bluebird bio, and Exelixis Shares Rebounded Last Friday
Motley Fool
Mon, 03/16/20 - 10:31 am
pharma stocks
AnaptysBio
Bluebird Bio
Exelixis
COVID-19
Asco-GU 2020: revving up for Peloton deal validation
EP Vantage
Thu, 02/13/20 - 10:46 am
ASCO-GU 2020
Merck
Peloton Therapeutics
Exelixis
Exelixis Reports Positive Results in Metastatic Castration-Resistant Prostate Cancer Study
Motley Fool
Wed, 02/12/20 - 10:27 am
Exelixis
prostate cancer
metastatic castration-resistant prostate cancer
cabozantinib
Cabometyx
JP Morgan Preview: Small, Medium and Large, with a Lot of M&A Speculation
BioSpace
Mon, 01/13/20 - 11:08 am
JPMHC 2020
M&A
Exelixis
Intercept Pharmaceuticals
Avidity Biosciences
Theravance
Moderna Therapeutics
Kodiak Sciences
Eyeing second Japanese approval, Daiichi and Exelixis announce positive pivotal for kidney drug
Endpoints
Fri, 11/8/19 - 10:40 am
Daiichi Sankyo
Exelixis
clinical trials
diabetic nephropathy
Minnebro
Renal Cell Carcinoma Space in Focus: Some Key Developments
Yahoo/Zacks.com
Sat, 09/14/19 - 11:18 am
renal cell carcinoma
kidney cancer
Exelixis
Roche
Merck
Aveo Oncology
Exelixis Hits Blockbuster Status
Motley Fool
Mon, 08/5/19 - 10:45 am
Exelixis
cabozantinib
Cabometx
kidney cancer
liver cancer
Cometriq
thyroid cancer
Exelixis Bolsters Pipeline in Deal with India's Aurigene
BioSpace
Fri, 08/2/19 - 12:20 am
Exelixis
Indian
Aurigene
Cabometyx
Roche/Exelixis' Cotellic fizzles in pivotal melanoma study
Endpoints
Fri, 06/21/19 - 10:07 am
Roche
Exelixis
Cotellic
Tecentriq
clinical trials
advanced melanoma
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »